Novel GLP-1/GIP Agent Led to Weight Loss With Once-Monthly Dosing

(MedPage Today) — CHICAGO — An investigational injectable that only requires dosing once every 4 weeks led to substantial weight loss in patients with obesity with or without type 2 diabetes, a phase II randomized trial showed.
In the obesity…

Source link : https://www.medpagetoday.com/meetingcoverage/ada/116194

Author :

Publish date : 2025-06-23 18:30:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30

Novel GLP-1/GIP Agent Led to Weight Loss With Once-Monthly Dosing

U.S. Neonatal Mortality Has Declined in Recent Years, Though Not For All Causes

Number of Abortions Kept Rising in 2024 Due to Telehealth Scripts, Report Says

Related Posts

Datroway Gains Second FDA Nod With NSCLC Approval

AID Systems Need Upgrades for Premenopausal Glucose Control

Metabolic Syndrome and Psoriatic Arthritis: Common but Unwanted Bedfellows

CMS Tightens Reins on Obamacare Access

Mifepristone Helped Control Diabetes in Those With Hypercortisolism

Ozempic Shows Benefit in Type 1 Diabetes Patients With Obesity

Datroway Gains Second FDA Nod With NSCLC Approval

AID Systems Need Upgrades for Premenopausal Glucose Control

Metabolic Syndrome and Psoriatic Arthritis: Common but Unwanted Bedfellows

CMS Tightens Reins on Obamacare Access

Test Predicts Cognitive Decline in Parkinson’s Disease

Mifepristone Helped Control Diabetes in Those With Hypercortisolism

Ozempic Shows Benefit in Type 1 Diabetes Patients With Obesity

Mice with two fathers have their own offspring for the first time

Categories

Archives